• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    3/7/23 8:06:29 AM ET
    $ADIL
    $AMAM
    $CARA
    $FSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ADIL alert in real time by email

    Gainers

    • Virax Biolabs Group (NASDAQ:VRAX) shares increased by 129.3% to $1.52 during Tuesday's pre-market session. The company's market cap stands at $19.4 million.
    • Adial Pharmaceuticals (NASDAQ:ADIL) shares moved upwards by 54.76% to $0.65. The company's market cap stands at $18.5 million.
    • Novo Integrated Sciences (NASDAQ:NVOS) stock rose 29.25% to $0.22. The market value of their outstanding shares is at $13.4 million.
    • Tenax Therapeutics (NASDAQ:TENX) stock moved upwards by 19.02% to $0.78. The market value of their outstanding shares is at $7.2 million.
    • F-star Therapeutics (NASDAQ:FSTX) shares increased by 14.91% to $7.01. The market value of their outstanding shares is at $154.0 million.
    • Unicycive Therapeutics (NASDAQ:UNCY) shares rose 10.48% to $1.37. The market value of their outstanding shares is at $20.6 million.

    Losers

    • Cara Therapeutics (NASDAQ:CARA) shares declined by 25.1% to $7.5 during Tuesday's pre-market session. The company's market cap stands at $403.0 million. As per the press release, Q4 earnings came out yesterday.
    • Xtant Medical Holdings (AMEX:XTNT) stock decreased by 16.3% to $0.77. The market value of their outstanding shares is at $83.6 million. As per the press release, Q4 earnings came out today.
    • Ambrx Biopharma (NYSE:AMAM) stock declined by 10.85% to $11.18. The market value of their outstanding shares is at $431.7 million.
    • Orchestra BioMed Hldgs (NASDAQ:OBIO) shares decreased by 10.24% to $16.32. The market value of their outstanding shares is at $515.9 million.
    • Marker Therapeutics (NASDAQ:MRKR) stock declined by 8.72% to $1.94. The company's market cap stands at $16.5 million.
    • Zynex (NASDAQ:ZYXI) stock decreased by 7.35% to $11.5. The market value of their outstanding shares is at $442.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADIL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADIL
    $AMAM
    $CARA
    $FSTX

    CompanyDatePrice TargetRatingAnalyst
    Orchestra BioMed Holdings Inc.
    $OBIO
    12/10/2025$15.00Buy
    TD Cowen
    Tenax Therapeutics Inc.
    $TENX
    9/8/2025$20.00Overweight
    Piper Sandler
    Orchestra BioMed Holdings Inc.
    $OBIO
    8/20/2025Buy → Neutral
    BTIG Research
    Zynex Inc.
    $ZYXI
    8/1/2025$3.70Neutral → Buy
    Ladenburg Thalmann
    Zynex Inc.
    $ZYXI
    8/1/2025Buy → Neutral
    H.C. Wainwright
    Unicycive Therapeutics Inc.
    $UNCY
    4/21/2025$6.00Buy
    Guggenheim
    Virax Biolabs Group Limited
    $VRAX
    3/31/2025$3.00Buy
    H.C. Wainwright
    Orchestra BioMed Holdings Inc.
    $OBIO
    3/20/2025$12.00Buy
    BTIG Research
    More analyst ratings

    $ADIL
    $AMAM
    $CARA
    $FSTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Schallenberger Mark A. covered exercise/tax liability with 7,709 shares, decreasing direct ownership by 1% to 663,157 units (SEC Form 4)

    4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)

    2/18/26 4:36:56 PM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Principal Accounting Officer Aiello Joshua

    4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

    2/13/26 5:02:11 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    Officer Sherman Darren was granted 397,000 shares, increasing direct ownership by 47% to 1,237,569 units (SEC Form 4)

    4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

    2/13/26 5:01:46 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    $ADIL
    $AMAM
    $CARA
    $FSTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen initiated coverage on Orchestra BioMed with a new price target

    TD Cowen initiated coverage of Orchestra BioMed with a rating of Buy and set a new price target of $15.00

    12/10/25 8:29:27 AM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    Piper Sandler initiated coverage on Tenax Therapeutics with a new price target

    Piper Sandler initiated coverage of Tenax Therapeutics with a rating of Overweight and set a new price target of $20.00

    9/8/25 8:59:21 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Orchestra BioMed downgraded by BTIG Research

    BTIG Research downgraded Orchestra BioMed from Buy to Neutral

    8/20/25 8:28:57 AM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    $ADIL
    $AMAM
    $CARA
    $FSTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Rich Stuart bought $50,792 worth of shares (5,000 units at $10.16), increasing direct ownership by 90% to 5,266 units (SEC Form 4)

    4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

    12/10/25 6:48:57 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Rich Stuart bought $45,622 worth of shares (5,000 units at $9.12), increasing direct ownership by 940% to 2,766 units (SEC Form 4)

    4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

    12/5/25 5:46:32 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO Giordano Christopher Thomas bought $20,000 worth of shares (2,605 units at $7.68) (SEC Form 4)

    4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

    11/20/25 6:38:51 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $AMAM
    $CARA
    $FSTX
    SEC Filings

    View All

    Adial Pharmaceuticals Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)

    3/6/26 8:15:35 AM ET
    $ADIL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Adial Pharmaceuticals Inc

    10-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)

    3/5/26 5:03:27 PM ET
    $ADIL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adial Pharmaceuticals Inc filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)

    3/3/26 8:17:24 AM ET
    $ADIL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $AMAM
    $CARA
    $FSTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update

    GLEN ALLEN, Va., March 06, 2026 (GLOBE NEWSWIRE) --  Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2025 fiscal year ended December 31, 2025. Key Highlights: Regulatory Progress: Achieved positive clinical study results from the AD04-103 pharmacokinetics (PK) study supporting AD04's pharmacologic profile and regulatory strategy.Received a positive response from the U.S. Food and Drug Administration (FDA) regarding the Company's proposed in vitro bri

    3/6/26 8:00:00 AM ET
    $ADIL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in Potential Royalties and Milestones upon execution of a Definitive Agreement

    GLEN ALLEN, Va., March 03, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction and related disorders, today announced it has entered into a collaboration framework agreement with Molteni Farmaceutici ("Molteni") for a proposed exclusive partnership covering the commercialization of AD04 in Europe. The collaboration framework, which is subject to execution of a final definitive agreement, sets forth the strategic and financial parameters of the planned partnership, covering clinical, regulatory, manufacturing, and commercial terms. Under the framework

    3/3/26 8:17:00 AM ET
    $ADIL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Orchestra BioMed Announces Presentations Highlighting AVIM Therapy Potential Impact on Hypertensive Heart Disease and Heart Failure at THT and CRT

    NEW HOPE, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced two presentations that will be given at the Technology Heart Failure and Therapeutics ("THT") and Cardiovascular Research Technologies ("CRT") 2026 Meetings highlighting the potential for the Company's Atrioventricular Interval Modulation Therapy ("AVIM Therapy") program in hypertensive heart disease and heart failure patients. Presentation at THT 2026Atrioventricular Interval Modulation

    3/3/26 8:00:00 AM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    $ADIL
    $AMAM
    $CARA
    $FSTX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for KORSUVA issued to CARA THERAPEUTICS INC

    Submission status for CARA THERAPEUTICS INC's drug KORSUVA (ORIG-1) with active ingredient DIFELIKEFALIN has changed to 'Approval' on 08/23/2021. Application Category: NDA, Application Number: 214916, Application Classification: Type 1 - New Molecular Entity

    8/24/21 12:36:58 PM ET
    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $AMAM
    $CARA
    $FSTX
    Leadership Updates

    Live Leadership Updates

    View All

    Zynex Announces Strategic Initiatives: Engagement of Province, Appointment of Paul Aronzon to Board of Directors, and Formation of Special Committee

    ENGLEWOOD, Colo., Nov. 14, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management and rehabilitation, today announced a series of strategic initiatives aimed at positioning Zynex for long-term success. Zynex has engaged Province, LLC, an internationally recognized financial advisory firm, to assist on evaluating a range of strategic alternatives, including potential capital raising opportunities and recapitalization and restructuring strategies. In add

    11/14/25 8:15:00 AM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors

    HOUSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the appointment of Kathryn Penkus Corzo, R.Ph., MBA to the Company's Board of Directors, effective November 1, 2025. Ms. Penkus Corzo has vast experience as a biopharma executive, drug developer and independent board director with more than 30 years of global leadership spanning R&D, clinical trials, regulatory approvals, commercialization, and corporate strategy across multiple therapeutic modalities and in

    11/5/25 7:30:00 AM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zynex Announces Appointment of Bret Wise to Board of Directors as Audit Committee Chair

    ENGLEWOOD, Colo., Oct. 14, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the appointment of Bret Wise to its Board of Directors. Mr. Wise will also serve as Chair of the Audit Committee. "Bret Wise is a great addition to our Board of Directors as the Chair of our Audit Committee as we continue to refocus the Zynex mission and vision around patient and customer success with a renewed comm

    10/14/25 6:07:00 PM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ADIL
    $AMAM
    $CARA
    $FSTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Tenax Therapeutics Inc.

    SC 13G - TENAX THERAPEUTICS, INC. (0000034956) (Subject)

    11/14/24 7:14:21 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Unicycive Therapeutics Inc.

    SC 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)

    11/14/24 7:13:38 PM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Unicycive Therapeutics Inc.

    SC 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)

    11/14/24 7:01:14 PM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $AMAM
    $CARA
    $FSTX
    Financials

    Live finance-specific insights

    View All

    Zynex Reports Third Quarter 2025 Financial Results

    ENGLEWOOD, Colo., Nov. 17, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, and rehabilitation, today reported its financial and operational results for the third quarter ended September 30, 2025. Management Commentary and Recent Events "Since joining the Company in August, the new management team has worked tirelessly to address the business and compliance challenges at Zynex while creating a new future for all our company," said Steven Dyson,

    11/17/25 5:15:00 PM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Zynex Sets Third Quarter 2025 Earnings Call

    ENGLEWOOD, Colo., Nov. 14, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management and rehabilitation, will hold a conference call on Tuesday, November 18, 2025 at 9:00 AM Eastern Time to discuss its financial results for the third quarter ended September 30, 2025. Financial results will be issued in a press release prior to the call. Zynex management will host the conference call. Date: Tuesday, November 18, 2025Time: 9:00 AM Eastern Time (7:00 PM Moun

    11/14/25 8:00:00 AM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    Phase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026 On Track to Initiate Second Phase 3 Study, LEVEL-2, in 2025 Tenax to Host Virtual KOL Call Tomorrow, Thursday, November 13, 2025 at 4:30 p.m. ET CHAPEL HILL, N.C., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today reported financial results for the quarter ended September 30, 2025 and provided an update on its recent corporate progress. "We c

    11/12/25 4:05:00 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care